4.3.4 Non-Invasive Prenatal Testing
Meredith Vanstone, PhD
Co-Authors: Mita Giacomini, PhD; and Jeff Nisker, MD, PhD, FRCSC, FCAHS
- Understand the ethical implications of private prenatal genetic tests that require support and services from the public system.
- Prepare a response to encountering patient requests for private-pay services that balances the best interests of your patient and the public health care system.
- Learn about the essential elements of supporting informed choices about NIPT and other prenatal tests.
Sally Smith is a 33 year old married mother of three. You have been her physician for many years, caring for her through all three pregnancies. By all observations she is a devoted mother who is delighted with her growing family. Her past medical history is unremarkable and she has no health concerns.
Ms. Smith presents at your office to confirm her fourth pregnancy. As you work through the questions and information you need to present at this first prenatal visit, she asks if she can have the new Down Syndrome test she has heard about, that will tell her whether or not her baby has Down Syndrome at 9 weeks gestation. You talk to her about some of the NIPT options, informing her that these tests are available from several companies for those who can pay privately, but they are not accurate enough to be considered diagnostic, and any results should be confirmed with an invasive diagnostic test such as amniocentesis or CVS. You also discuss how NIPT compares to publicly-funded non-invasive prenatal screening tests, including differences in detection rate, timing, and cost. Ms. Smith has lots of questions about her options and her visit quickly runs over the allotted time as you discuss the various differences between NIPT and conventional screening tests. Ms. Smith decides to go home and think about the information further, as she wants to discuss the tests with her husband and look more closely at their family budget. You agree that if she wants to proceed with one of the tests, she will re-book to complete the necessary paperwork.
- You are now late for your next patient and will end up playing catch-up all day, due to the time you spent discussing NIPT with Ms. Smith. You are committed to spending as much time with each patient as needed, but does this apply when that time is spent discussing a private test?
- NIPT is not publicly funded in most jurisdictions, but it can be obtained privately. If a patient pays privately for NIPT, they may gain earlier access to some public services, such as counselling services and pregnancy termination. Do you consider this preferential treatment? Does it seem a fair and equitable use of public resources?
- When you do counsel about NIPT, how can you discuss this testing option to best facilitate informed decision-making by your patients?
NIPT is an example of a test which is only available to women who can pay privately in most Canadian jurisdictions. In some jurisdictions, such as Ontario, it is available publicly if a woman is identifiably at high risk. In this case, your patient has an average risk for fetal aneuploidy.
- Vanstone M, King C, de Vrijer B, Nisker J. Non-Invasive Prenatal Testing: Ethics and Policy Considerations. J Obstet Gynaecol Can. 2014;36(6):515-26.
- Wright C, Wei Y, Higgins J, Sagoo G. Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis. BMC Res Notes. 2012;5(1):476.
- Langlois S, Brock J. Current status in non-invasive prenatal detection of Down syndrome, Trisomy 18 and Trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can. 2013;35(2):177-81.
- Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, et al. Position statement from the aneuploidy screening committee on behalf of the board of the international society for prenatal diagnosis, April 2013. Prenat Diagn. 2013;32:1-2.
- American College of Obstetricians and Gynecologists. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No.545. Obstet Gynecol. 2012;120:1532-4.
- Chitayat D, Langlois S, Wilson RD. Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies. J Obstet Gynaecol Can. 2011;33(7):736.
- Wilson RD, Langlois S, Johnson JA, Society of O, Gynaecologists of C. Mid-trimester amniocentesis fetal loss rate. JObstetGynaecolCan. 2007;29(7):586-95.
- Nicolaides K, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005;25(3):221-6.
- Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med. 2012;14(3):296-305.
- Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011;13(11):913-20.
- Gamma Dynacare. OHIP now covers payments for the Harmony Prenatal Test. Laval, Quebec: Gamma Dynacare, 2014 January 27, 2014. Report No.: Contract No.: 52.
- Devers PL, Cronister, Amy., Ormond, Kelly, E., Facio, Flavia., Brasington, Campbell K., Flodman, Pamela. . Noninvasive prenatal testing/Noninvasive prenatal diagnosis: The position of the National Society of Genetic Counselors. J Genet Couns. 2013:1-5.
- Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters. 2008;16(31):173-82.
- Mentula MJ, Niinim�ki M, Suhonen S, Hemminki E, Gissler M, Heikinheimo O. Immediate adverse events after second trimester medical termination of pregnancy: results of a nationwide registry study. Hum Reprod. 2011;26(4):927-32.
- Davies V, Gledhill J, McFadyen A, Whitlow B, Economides D. Psychological outcome in women undergoing termination of pregnancy for ultrasound-detected fetal anomaly in the first and second trimesters: a pilot study. Ultrasound Obstet Gynecol. 2005;25(4):389-92.
- Frank JR. The CanMEDS 2005 physician competency framework. Better standards. Better physicians. Better care. Ottawa, Canada: The Royal College of Physicians and Surgeons of Canada, 2005 Contract No.: Report.
- Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001;4(2):99-108.
- Toews M, Caulfield T. Physician Liability and Non-Invasive Prenatal Testing. J Obstet Gynaecol Can. 2014;36(10):907-14.
- Vanstone M, Kinsella EA, Nisker J. Information-Sharing to Promote Informed Choice in Prenatal Screening in the Spirit of the SOGC Clinical Practice Guideline: A Proposal for an Alternative Model. J Obstet Gynaecol Can. 2012;34(3):269-75.
- Cartier L, Murphy-Kaulbeck L, Wilson R, Audibert F, Brock J, Carroll J, et al. Counselling considerations for prenatal genetic screening. Journal of obstetrics and gynaecology Canada: JOGC= Journal d'obst�trique et gyn�cologie du Canada: JOGC. 2012;34(5):489.
- Marteau TM, Dormandy E. Facilitating informed choice in prenatal testing: how well are we doing? Am J Med Genet. 2001;106(3):185-90.
- Potter BK, Oâ€™Reilly N, Etchegary H, Howley H, Graham ID, Walker M, et al. Exploring informed choice in the context of prenatal testing: findings from a qualitative study. Health Expect. 2008;11(4):355-65.
- Schoonen HMHJD, van Agt HME, Essink-Bot M, Wildschut HI, Steegers EAP, de Koning HJ. Informed decision-making in prenatal screening for Down's syndrome: What knowledge is relevant? Patient Educ Couns. 2011;84(2):265-70.
- van den Berg M, Timmermans DRM, ten Kate LP, van Vugt JMG, van der Wal G. Informed decision making in the context of prenatal screening. Patient Educ Couns. 2006;63(1-2):110-7.
- Deans Z, Newson AJ. Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Anal. 2011;19(2):122-32.
- van den Heuvel A, Chitty L, Dormandy E, Newson A, Deans Z, Attwood S, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns. 2010;78(1):24-8.
- Cavanagh JP, Mathews M. Maternal serum screening in Newfoundland and Labrador. Can Fam Physician. 2006;52(Journal Article):1269e:1-e:6.
- Schmitz D, Netzer C, Henn W. An offer you can't refuse? Ethical implications of non-invasive prenatal diagnosis. Nature Reviews Genetics. 2009;10(8):515-.
- Gregg AR, Best R, Monaghan K, Bajaj K, Skotko B. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. congenital anomalies. 2013;16:19.
Short Author Biographies
Meredith Vanstone is an Assistant Professor in the Department of Clinical Epidemiology and Biostatistics and a member of the Centre for Health Economics and Policy Analysis at McMaster University. Her research interests include social and ethical aspects of health technology policy, reproductive and genetic technologies, and the use of technology in health professional education and practice. Meredith approaches research from a socio-cultural perspective, using qualitative methods to analyze both primary and secondary data.
Mita Giacomini is a Professor in Clinical Epidemiology and Biostatistics at McMaster University, and a member of the Centre for Health Economics and Policy Analysis. She led the development of McMaster's Health Policy PhD program and previously served as its Director. She holds graduate degrees in health services and policy analysis, history of medicine and public health. Her publications have addressed topics including health policy ethics, political reasoning in health technology assessment, health resource allocation, values in evaluation and policy-making, interdisciplinarity, and uses of qualitative evidence in health care. Current research projects focus on the roles of evidence and theory in health policy arguments, values and ethics in Canadian health policy, and the social and ethical dimensions of health technology assessment. Giacomini has provided consultation and service to local, provincial, national and international health agencies in related areas. She currently serves on the Ontario Health Technology Advisory Committee. Giacomini teaches in the areas of health policy, philosophy of science, and research methodology.
Jeff Nisker is a Professor of Obstetrics-Gynaecology at the Schulich School Medicine & Dentistry, Western University, and Scientist, Children�s Health Research Institute. He holds, and has held, CIHR and Genome Canada grants to explore ethical and social issues in reproductive medicine, genetics, and exposure of pregnant women to environmental toxins. He has held a CIHR/Health Canada grant exploring public engagement for citizen deliberation regarding pre-implantation genetic diagnosis. Jeff has written or co-written over 150 scientific articles and book chapters, as well as seven plays. His plays have been performed throughout Canada, as well as in the United States, the United Kingdom, Australia and South Africa.
Support for this work was received from the Canadian Institutes of Health Research. Meredith Vanstone�s salary is supported by the Ontario Ministry of Health and Long Term Care through a Health Systems Research Fund grant entitled �Harnessing Evidence and Values for Health System Excellence�. The views expressed in this document are the views of the authors and should not be taken to represent the views of the Ministry of Health and Long Term Care.